O'Dell Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

O'Dell Group’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	592
2022 Q1	$0	Hold	1	–	–	﹤0.01%	598
2021 Q4	$0	Buy	+1	New	+$9	﹤0.01%	561

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

O'Dell Group's EVFM Position: Q2 2022 in Review

O'Dell Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1 share.

O'Dell Group first reported a position in EVFM in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

O'Dell Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
O'Dell Group sold 1 Evofem Biosciences, Inc. Common Stock share in Q2 2022.
O'Dell Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
O'Dell Group's Evofem Biosciences, Inc. Common Stock position peaked at $0 in Q1 2022.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on O'Dell Group's 13F filing for Q2 2022, filed 11 Aug 2022.